Cream to Treat Anal Fissures Meets Late-Stage Goal
Print This Email this
36% of US physicians said that they have minimal to no savings.
See what else our Physician Lifestyle Report reveals about family life, spending habits, religious beliefs, and more. View report >
(Reuters) May 14 – Drugmaker Ventrus Biosciences Inc said its cream to treat anal fissures met the main goal of reducing pain in a late-stage trial.
The cream, diltiazem hydrochloride, was tested on 465 patients with anal fissures – tears in the anal lining that can cause severe anal pain, associated with or after bowel movements.
Codenamed VEN 307, the cream is being developed with Ventrus’ partner S.L.A. Pharma.
Ventrus said it plans to meet with the U.S. Food and Drug Administration to discuss the steps toward filing for approval.